White Paper

Single-Use Systems For Vaccine Manufacturing

Source: Sartorius

By J. Cappia, C. Langlois, M. Hogreve, A. Hauk, and K. Wormuth

Sartorius supplied AdobeStock_29353597

To meet global demand, it is predicted that next generation vaccines will be based on recombinant approaches and be produced in intensified single-use systems (SUS) to increase capacity at reduced costs. However, despite their benefits, SUS for vaccine manufacturing face a number of key regulatory challenges, which require greater reliance by the biopharmaceutical industry on SUS suppliers.

This article details how Sartorius Stedim Biotech (SSB) is leveraging its quality strategy to address these issues by partnering with polymer and film suppliers to combine material science, film extrusion and bag making expertise, allowing in-depth characterization and process control of extractables/leachables substances and particles profiles of its SUS. The article also discusses why process controls, integrity testing and Maximum Allowable Liquid Leakage (MALL) specifications integrated with a solid global supply network will help the biopharmaceutical industry to achieve a more consistent quality supply of SUS for the production of safe, affordable vaccines.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online